Age related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 6, 1997, Pages 505-512

  Cusack, Barry J ^a,b,c   Young, Stephan P ^a   Vestal, Robert E ^a,b,c   Olson, Richard D ^a,b,c  

^a Boise VA Medical Center   (United States)

^b St Luke's Mountain States Tumor Institute   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Anthracyclines; Daunorubicin; Daunorubicinol; Pharmacokinetics; Rat

Indexed keywords

DAUNORUBICIN; DAUNORUBICINOL; DRUG METABOLITE;

AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CARDIOTOXICITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG TISSUE LEVEL; HEART; HEART MUSCLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

AGING; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; CARDIOMYOPATHIES; DAUNORUBICIN; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE; RATS; RATS, INBRED F344;

EID: 0031016894     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050606     Document Type: Article

References (42)

1. Bachur NR, Gee M (1976) Microsomal reductive glycosidase. J Pharmacol Exp Ther 197:681
2. Bielack SS, Erttman R, Winkler K, Landbeck G (1989) Doxorubicin: effect of different schedules on toxicity and antitumor efficacy. Eur J Clin Oncol 25:873
3. Boucek RJ Jr, Olson RD, Brenner DE, Ogunbunmi EM, Inui M, Fleischer S (1987) The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. J Biol Chem 262:15851
4. Bristow MR, Mason JW, Billingham ME, Daniels JR (1978) Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 88:168
5. Colombo T, Donelli MG, Urso R, Dallarda S, Bartosek B, Guitani A (1989) Doxorubicin toxicity and pharmacokinetics in old and young rats. Exp Gerontol 24:159
6. Cusack BJ, Tesnohlidek DA, Loseke VL, Vestal RE, Brenner DE, Olson RD (1988) Effects of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. Cancer Chemother Pharmacol 22:294
7. Cusack BJ, Young SP, Loseke VL, Hurty MR, Olson RD (1992) Effect of low-protein diet on doxorubicin pharmacokinetics in the rabbit. Cancer Chemother Pharmacol 30:145
8. Cusack BJ, Mushlin PS, Voulelis LD, Li X, Boucek RJ Jr, Olson RD (1993) Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol? Toxicol Appl Pharmacol 118:177
9. Cusack BJ, Young SP, Driskell J, Olson RD (1993) Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 32:53
10. Cusack BJ, Young SP, Olson RD (1995) Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat. Cancer Chemother Pharmacol 35:213
11. De Jong J, Schoofs PR, Snabile AM, Bast A, Vijgh WJE van der (1993) The role of biotransformation in anthracycline-induced cardiotoxicity in mice. J Pharmacol Exp Ther 266:1312
12. Dodd DA, Atkinson JB, Olson RD, Buck S, Cusack BJ, Fleischer S, Boucek RJ Jr (1993) Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. J Clin Invest 91:1697
13. Dresdale A, Bonow RO, Wesley R, Palmeri ST, Barr L, Mathison D, D'Angelo T, Rosenberg SA (1983) Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. Cancer 52:51
14. Froelich JP, Lakatta EG, Beard E, Spurgeon HA, Weisfeldt ML, Gerstenblith G (1978) Studies of sarcoplasmic reticulum function and contraction duration in young and aged rat myocardium. J Mol Cell Cardiol 10:427
15. Gibaldi M (1985) Biopharmaceutics and clinical pharmacokinetics. Lea & Feiberger, Philadelphia, p 17
16. Gerwitz DA, Yanovich S (1986) Metabolism of the anthracycline antibiotic daunorubicin to daunorubicinol and deoxydaunorubicinol aglycone in hepatocytes isolated from the rat and the rabbit. Biochem Pharmacol 22:4059
17. Goodman J, Hochstein P (1977) Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin. Biochem Biophys Res Commun 77:797
18. Gupta S (1995) P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy. Drugs Aging 7:19
19. Hazelton GA, Lang CA (1980) Glutathione contents in tissues in the aging mouse. Biochem J 188:25
20. Hazelton GA, Lang CA (1985) Glutathione peroxidase and reductase activities in the aging mouse. Mech Ageing Dev 29:71
21. Jiang M-T, Narayanan N (1990) Effects of aging on phospholamban phosphorylation and calcium transport in rat cardiac sarcoplasmic reticulum. Mech Ageing Dev 54:87
22. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96:133
23. Lum RL, Gosland MP (1995) MDR expression in normal tissues. Pharmacological implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin N Am 9:319
24. Meyers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC (1977) Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197:165
25. Mihranian MH, Wang YM, Daly JM (1984) Effects of nutritional depletion and repletion on plasma methotrexate pharmacokinetics. Cancer 54:2268
26. Minotti G, Cavaliere AF, Mordente A, Rossi M, Schiavello R, Zamparelli R, Posatti GF (1995) Secondary alcohol metabolites mediate iron delocalisation in cytosolic fractions of myocardial biopsies exposed to anticancer drugs. Novel link between anthracycline metabolism and iron-induced cardiotoxicity. J Clin Invest 95:1595
27. Nooter K, Sonneveld S, Martens A (1985) Effects of verapamil on the pharmacokinetics of daunorubicin in the rat. Cancer Chemother Pharmacol 20:176
28. Olson RD, Brenner DE, Cusack BJ, Mushlin PS, Andrejuk T, Boucek RJ (1987) Effect of daunorubicinol on myocardial function. Proc Am Assoc Cancer Res 28:441
29. Olson RD, Mushlin PS, Brenner DE, Fleischer S, Cusack BJ, Chang BK, Boucek RJ Jr (1988) Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 85:3585
30. Palmeri ST, Bonow RO, Myers CE, Seipp C, Jenkins J, Green MV, Bacharach SL, Rosenberg SA (1986) Prospective evaluation of doxorubicin cardiotoxicily by rest and exercise radionuclide angiography. Am J Med 58:607
31. Pilarski LM, Paine D, McElhaney JE, Cass CE, Belch AR (1995) Multidrug transporter P-glycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes: modulation with differentiation stace and during aging. Am J Hematol 49:323
32. Robert J, Hoerni B (1983) Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res 43:4467
33. Robert J, Bui NB, Vrignaud P (1987) Pharmacokinetics of doxorubicin in sarcoma patients. Eur J Clin Pharmacol 31:695
34. Schmucker DL (1985) Aging and drug disposition: an update. Pharmacol Rev 37:13
35. Sonawane BR, Yaffe SJ (1983) Endotoxin and low protein diet induced depression of the rat hepatic drug metabolism. Pharmacology 26:100
36. Stewart DL, Grewaal D, Green RM, Mikhael N, Goel R, Montpetit VA, Redmond MD (1993) Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues. Anticancer Res 13:1945
37. Stohs J, Hassing JM, Al-turk WA, Mosoud AM (1980) Glutathione levels in hepatic and extrahepatic tissues of mice as a function of age. Age 3:11
38. Stohs J, Al-Turk WA, Angle CR (1982) Glutathione S-transferase and glutathione reductase activities in hepatic and extrahepatic tissues of female mice as a function of age. Biochem Pharmacol 31:2113
39. Storm G, Hoesel QGCM van, Groot G de, Kop W, Steerenberg PA, Hüllen FC (1989) A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/Wistar rat. Cancer Chemother Pharmacol 24:341
40. Vestal RE, Cusack BJ (1990) Pharmacology and aging. In: Schneider EL, Rowe JW (eds) Handbook of the biology of aging. 3rd edn. Academic Press, San Diego, p 349
41. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozeneweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710
42. Weinberg LE, Singal PK (1987) Refractory heart failure and age-related difference in adriamycin-induced myocardial changes in rats. Can J Physiol Pharmacol 65:1957